{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:07:13Z","timestamp":1771513633186,"version":"3.50.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T00:00:00Z","timestamp":1764720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.bulcan.2025.09.005","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T12:28:56Z","timestamp":1766406536000},"page":"175-190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Faisabilit\u00e9 de l\u2019administration du carfilzomib en hospitalisation \u00e0 domicile dans la prise en charge du my\u00e9lome multiple (\u00e9tude Carfil-HAD)"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2208-2345","authenticated-orcid":false,"given":"Mohamed","family":"Touati","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Camille","family":"Villesuzanne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ga\u00eblle","family":"Maillan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Dmytruk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Streicher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Brillat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederica","family":"Bompart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cindy","family":"Chauvet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Tisseuil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Sardin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aur\u00e9lie","family":"Perraud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Bastide","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludovic","family":"Lamarsalle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aude","family":"Massoulard-Gainant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Girault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Murielle","family":"Roussel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2025.09.005_bib0185","unstructured":"Institut national du cancer. Strat\u00e9gie D\u00e9cennale de Lutte contre les Cancers 2021-2030. vol. Feuille de Route 2021-2025. https:\/\/sante.gouv.fr\/IMG\/pdf\/feuille_de_route_-_strategie_decennale_de_lutte_contre_les_cancers.pdf."},{"key":"10.1016\/j.bulcan.2025.09.005_bib0190","series-title":"Survie des personnes atteintes de cancer en France m\u00e9tropolitaine (1989\u20132018)\u00a0\u2013\u00a0my\u00e9lome multiple et plasmocytome","author":"Monnereau","year":"2023"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0195","series-title":"Improved survival in multiple myeloma and the impact of novel therapies","first-page":"2516","author":"Kumar","year":"2008"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0200","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","article-title":"Multiple myeloma current treatment algorithms","volume":"10","author":"Rajkumar","year":"2020","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0205","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1080\/17474086.2021.2022471","article-title":"The development of a home-based therapeutic platform for multiple myeloma","volume":"14","author":"Beer","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0210","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0215","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.clml.2025.03.004","article-title":"Survival, years of life lost and attrition rates in multiple myeloma patients in France","volume":"25","author":"Perrot","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0220","first-page":"5581","article-title":"Impacts on health outcomes and on resources utilization for anticancer drugs injection at home, a complex intervention: a systematic review","volume":"29","author":"Mittaine-Marzac","year":"2021","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0225","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/NHH.0000000000000958","article-title":"Patient safety and satisfaction in home chemotherapy","volume":"39","author":"Sanguinetti","year":"2021","journal-title":"Home Healthc Now"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0230","unstructured":"Haute Autorit\u00e9 Sant\u00e9. Conditions du d\u00e9veloppement de la chimioth\u00e9rapie en Hospitalisation \u00e0 Domicile\u00a0: analyse \u00e9conomique et organisationnelle 2015. https:\/\/www.has-sante.fr\/jcms\/c_1696038\/fr\/conditions-du-developpement-de-la-chimiotherapie-en-hospitalisation-a-domicile."},{"key":"10.1016\/j.bulcan.2025.09.005_bib0235","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Algorithme d\u2019aide \u00e0 la d\u00e9cision d\u2019orientation des patients en HAD \u00e0 destination des m\u00e9decins prescripteurs 2017. https:\/\/www.has-sante.fr\/jcms\/c_2810323\/fr\/algorithme-d-aide-a-la-decision-d-orientation-des-patients-en-had-a-destination-des-medecins-prescripteurs."},{"key":"10.1016\/j.bulcan.2025.09.005_bib0240","unstructured":"Touati M. Comment l\u2019hospitalisation \u00e0 domicile devient incontournable en oncoh\u00e9matologie, \u00e0 l\u2019heure du virage ambulatoire\u00a0? 2018. https:\/\/horizonshemato.com\/wp-content\/uploads\/2018\/07\/Comment-l%E2\u00a0%80\u00a0%99hospitalisation-%C3\u00a0%A0-domicile-devient-incontournable-en-onco-h%C3\u00a0%A9matologie-%C3\u00a0%A0-l%E2\u00a0%80\u00a0%99heure-du-virage-ambulatoire.pdf."},{"key":"10.1016\/j.bulcan.2025.09.005_bib0245","doi-asserted-by":"crossref","first-page":"103588","DOI":"10.1016\/j.breast.2023.103588","article-title":"Cost effectiveness of using trastuzumab biosimilars compared to trastuzumab original drugs to treat breast cancer in a hospital setting","volume":"72","author":"Barat","year":"2023","journal-title":"Breast Edinb Scotl"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0250","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.14409","article-title":"Home-based daratumumab in patients with multiple myeloma","volume":"115","author":"Rosenberg","year":"2025","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0255","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/s10238-025-01683-2","article-title":"Ten-year experience on home care for patients with plasma cell disorders: bringing optimal therapy home","volume":"25","author":"Bigi","year":"2025","journal-title":"Clin Exp Med"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0260","series-title":"Rapport d\u2019activit\u00e9 2022-2023","year":"2023"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0265","unstructured":"FNEHAD. Rapport d\u2019activit\u00e9 2023-2024. https:\/\/heyzine.com\/flip-book\/d62afab9f6.html."},{"key":"10.1016\/j.bulcan.2025.09.005_bib0270","series-title":"La FHF officialise le lancement de FHF HAD","year":"2024"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0275","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/annonc\/mdv563","article-title":"Home administration of bortezomib in multiple myeloma is cost-effective and is preferred by patients compared with hospital administration: results of a prospective single-center study","volume":"27","author":"Lassalle","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0280","first-page":"5007","article-title":"Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in outpatient hospital and hospital care at home","volume":"24","author":"Touati","year":"2016","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0285","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.critrevonc.2018.03.011","article-title":"Organization, quality and cost of oncological home-hospitalization: a systematic review","volume":"126","author":"Cool","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0290","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2165\/00019053-200119080-00006","article-title":"Incremental cost analysis of ambulatory clinic and home-based intravenous therapy for patients with multiple myeloma","volume":"19","author":"Coyte","year":"2001","journal-title":"PharmacoEconomics"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0295","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bulcan.2021.09.014","article-title":"Proposal for a general framework for the administration of anticancer immunotherapy in a hospital-at-home care","volume":"109","author":"Toffart","year":"2022","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0300","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.bulcan.2021.09.012","article-title":"Immune checkpoint inhibitors and hospitalization at home in France","volume":"109","author":"Gobbini","year":"2022","journal-title":"Bull Cancer (Paris)"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0305","unstructured":"Haute Autorit\u00e9 de sant\u00e9. Chimioth\u00e9rapie injectable en HAD - Monographie des HAD du Limousin dans le cadre du r\u00e9seau d\u2019h\u00e9matologie du Limousin HEMATOLIM via le dispositif ESCADHEM 2014. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2015-03\/chimiotherapie_injectable_en_had_-_monographie_des_had_du_limousin_dans_le_cadre_du_reseau_dhematologie_du_limousin_hematolim_via_le_dispositif_escadhem.pdf."},{"key":"10.1016\/j.bulcan.2025.09.005_bib0310","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0315","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0320","unstructured":"CHIMIO\u00a9\u00a0: Computer Engineering https:\/\/www.computer-engineering.fr\/applications\/chimio\/."},{"key":"10.1016\/j.bulcan.2025.09.005_bib0325","unstructured":"Haute Autorit\u00e9 Sant\u00e9. Mesure de la satisfaction et de l\u2019exp\u00e9rience des patients hospitalis\u00e9s plus de 48\u00a0heures en M\u00e9decine Chirurgie Obst\u00e9rique 2021. https:\/\/www.has-sante.fr\/upload\/docs\/application\/pdf\/2021-12\/iqss_2021_rapport_resultats_nationaux_esatis48hmco_2021.pdf."},{"key":"10.1016\/j.bulcan.2025.09.005_bib0330","series-title":"Evaluation de la satisfaction des patients atteints d\u2019h\u00e9mopathie maligne b\u00e9n\u00e9ficiant de chimioth\u00e9rapies injectables \u00e0 domicile\u00a0: exp\u00e9rience du dispositif ESCADHEM du R\u00e9seau HEMATOLIM","author":"Touati","year":"2014"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0335","article-title":"Cost Saving with home-based chemotherapy approach in multiple myeloma. The ADHOMY Trial","author":"Schulmann","year":"2024","journal-title":"J Pharm Pharmacol Res"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0340","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1080\/13696998.2022.2133823","article-title":"Beyond medicines\u2019 barriers: exploring the true cost of multiple myeloma","volume":"25","author":"Choon-Quinones","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0345","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1186\/s12913-025-12935-y","article-title":"Facilitators and barriers to provision of hospital in the home: does geographical location matter? A scoping review","volume":"25","author":"Glenister","year":"2025","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0350","doi-asserted-by":"crossref","first-page":"1335344","DOI":"10.3389\/fonc.2024.1335344","article-title":"National expert consensus on home-administered oncologic therapies in Spain","volume":"14","author":"Villegas","year":"2024","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.bulcan.2025.09.005_bib0355","first-page":"CD014861","article-title":"Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer","volume":"4","author":"Grobler","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bulcan.2025.09.005_bib0180","unstructured":"D\u00e9cret n\u00b0 2025-114\u00a0du 5\u00a0f\u00e9vrier 2025\u00a0relatif \u00e0 l\u2019exp\u00e9rimentation pr\u00e9vue \u00e0 l\u2019article 50\u00a0de la loi no\u00a02023-1250\u00a0de financement de la s\u00e9curit\u00e9 sociale pour 2024. https:\/\/www.legifrance.gouv.fr\/jorf\/id\/JORFTEXT000051141778."}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512500476X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000745512500476X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:14:15Z","timestamp":1771510455000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000745512500476X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S000745512500476X"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.09.005","relation":{},"ISSN":["0007-4551"],"issn-type":[{"value":"0007-4551","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Faisabilit\u00e9 de l\u2019administration du carfilzomib en hospitalisation \u00e0 domicile dans la prise en charge du my\u00e9lome multiple (\u00e9tude Carfil-HAD)","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2025.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}